MedTrace Logo

Safety Study of Galantamine in Tic Disorders

NCT00226824 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2009-08-25

No results posted yet for this study

Summary

The purpose of this study is to determine the safety, tolerability and efficacy of galantamine in tic disorders. The impact of galantamine on commonly associated behaviors (i.e. attention, obsessions, etc.) will also be examined.

Conditions

  • Tourette's Syndrome
  • Motor Tic Disorder
  • Vocal Tic Disorder

Interventions

DRUG

galantamine

Sponsors & Collaborators

  • Ortho-McNeil Neurologics, Inc.

    collaborator INDUSTRY

  • Parkinson's Disease and Movement Disorders Center

    lead OTHER

Principal Investigators

  • Donald S Higgins, M.D. · Parkinson's Disease and Movement Disorder Center of Albany Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2007-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00226824 on ClinicalTrials.gov